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1066-189 Elevation of Plasma Adrenomedullin Level Is Closely 
Related to C-Reactive Protein and Interleukin-6 in 
Patients With Peripheral Arterial Occlusive Disease
Yoshihiko Suzuki, Takeshi Horio, Tanenao Eto, Kenji Kangawa, Yuhei Kawano, Miyazaki 
Medical College, Miyazaki, Japan
Background: Adrenomedullin (AM) is known to have anti-atherosclerotic and anti-
inflammatory effects. Although previous studies have shown that plasma AM levels are
elevated in various diseases, there are no data about its level in patients with peripheral
arterial occlusive disease (PAOD), one of severe atherosclerotic diseases. Methods and
Results: We examined 33 patients with PAOD and 39 patients without PAOD. Between
the two groups, there was no significant difference in clinical and laboratory parameters
except serum creatinine and ankle brachial index (ABI). The plasma AM concentration in
PAOD group was significantly higher than in non-PAOD group (11.5 ± 3.0 vs. 9.5 ± 2.2
fmol/mL, p<0.01). Its level had a correlation with the severity of PAOD, i.e., with ABI (r=-
0.39, p<0.01) and Fontaine classification (r=0.32, p<0.01). Furthermore, plasma AM was
significantly correlated with C-reactive protein and interleukin-6 (figure). By multiple
regression analysis, ABI and IL-6 were independent determinants of the plasma level of
AM. Conclusions: The plasma AM concentration was elevated in patients with PAOD in
proportion to the severity. The AM level was also associated with CRP and IL-6, markers
of inflammation. Recent studies showed that elevation of inflammatory parameters, such
as CRP and IL-6, was strongly related to future cardiovascular events. Therefore, an
increased production of AM in patients with PAOD may play a protective role against
advanced atherosclerosis with inflammatory signature.
1066-190 Influence of Statin Therapy on Arterial Elasticity in 
Essential Hypertension
Malgorzata Kurpesa, Zbigniew Bednarkiewicz, Maria Krzeminska-Pakula, Medical 
University, Lodz, Poland
Background: The vascular remodeling is a common problem in patients (pts) with arterial
hypertension (HA). Statins by influence on migration and proliferation of smooth muscle
cells may inhibit the posthypertensive arterial remodeling. Pulse wave velocity (PWV)
provides an indirect, non-invasive measurement of the mechanical properties of arteries.
The aim of the study was to evaluate the influence of statins on arterial elasticity in HA.
Methods: The study group consisted of 52 pts with essential moderate HA. They were
randomised into Group I (26 pts who received statin) and Group II (26 pts who received
placebo). Groups were comparable according to age, gender, blood pressure values and
treatment of HA. Before and following 6 months of treatment PWV was evaluated using a
computer system COMPLIOR. For automatic measurement of PWV pressure waveforms
were digitized at rate 500 Hz for carotid-femoral distance. 10 healthy volunteers consti-
tuted a control group.
Results: After 6 months similar reduction of BP was observed in both groups. Following 6
months of conventional treatment of HA the PWV was slightly decreased. Addition of sta-
tin caused the significant reduction of PWV. (*p<0.01)
Conclusions: 1. Addition of statin to conventional treatment may improve arterial elasticity
in essential HA.
2. Statins are likely to inhibit posthypertensive arterial remodeling
1066-191 A Phase I Study of Intramuscular Administration of 
Plasmid, Developmentally Regulated Endothelial Cell 
Locus-1 Gene, in Humans With Peripheral Arterial 
Disease
Sanjay Rajagopalan, Jeffrey Snell, Marc Litt, Gary L. Schaer, Ronald Karlsberg, Suheil 
Dohad, Stuart W. Young, Valentis Inc., Burlingame, CA
Background: Developmentally regulated endothelial locus 1( Del-1) is a novel angioma-
trix protein. Preclinical studies using a plasmid expressing Del-1 (VLTS–589) in conjunc-
tion with a poloxamer have demonstrated functional improvements in lower extremity
perfusion and exercise tolerance. The objective of this investigation was to assess the
safety of VLTS-589 in subjects with peripheral arterial disease (PAD).
Methods: Subjects with either intermittent claudication (Rutherford 2 and 3, n=18) or crit-
ical limb ischemia (resting pain, Rutherford 4, n=9) were enrolled in an open-label, dose
escalation, 90 day follow-up study after exclusion of conditions that may preclude angio-
genic growth factor delivery (malignancy, retinopathy etc.). 27 subjects received IM injec-
tions in 1 lower extremity (3 to 84 mg, 7 cohorts, C1-C6b; circumferential [C6a] and
posterior, linear [C6b] pattern of injections).
Results: There were no serious adverse events attributable to VTLS-589; no subjects
required amputation. Transient ecchymosis at the injection site, noted in 4 subjects, was
attributed to the injection procedure. Changes in mean peak walking time (PWT) for sub-
jects able to exercise and Ankle/Brachial Index (ABI) data for the entire cohort is reported
below in Table 1. 
Conclusion: IM delivery of up to 84 mg VLTS-589 is well tolerated. These data sup-
ported a controlled Phase II clinical trial (DELTA-1 or Del-1 for Therapeutic Angiogene-
sis), which is currently in progress.
1066-192 Effect of Enzyme Replacement Therapy on Intima Media 
Thickness and Endothelial Function in Fabry Disease
Remy Chenevard, Jr., David Hurlimann, Jr., Urs Widmer, Sr., Frank Ruschitzka, Sr., 
Georg Noll, Sr., University Hospital Zurich, Zurich, Switzerland
Background: Fabry disease is an inborn lysosomal storage disorder with deposition of
glycosphingolipids in the vascular system including endothelial- and smooth muscle
cells, possibly leading to endothelial dysfunction. We tested the hypothesis whether
enzyme replacement therapy (ERT) with agalsidase would alter vascular function.
Methods: Flow mediated vasodilatation (FMD) of the radial artery was assessed using
high-resolution ultrasound; nitroglycerine (NG) sublingually induced endothelium inde-
pendent vasodilatation. Results are expressed as percent change of diameter from base-
line. Intima-media thickness of the brachial artery (IMT) was calculated with a vessel wall
detection software.
Results: 13 hemizygote and 10 heterozygote patients were compared before and after
0.9 years of ERT to 15 age and risk factors matched healthy subjects. Hemizygote Fabry
patients presented with greater IMT at baseline compared to control and heterozygote
patients (470 ±34 µm vs. 401 ±13 µm and 402 ±10 µm; p=0.029 and p=0.049); FMD in
hemizygote and to a less extent in heterozygote patients tended to be impaired versus
control (5.4 ±0.9% and 6.1 ±0.9% vs. 8.2 ±1.2%; p=0.09 and p=0.19). ERT led to normal-
isation of IMT in hemizygote patients (397 ±12 µm; p=0.05) but had no effect on endothe-
lial function (5.0 ±1.2%; p=0.7). IMT correlated inversely with FMD in the control group
(r2=0.411), but not in Fabry patients (r2<0.01).
Conclusions: One year of ERT reduced IMT in hemizygote patients but had no effect on
endothelial function. Our data suggest that structural changes seen in Fabry disease are
unrelated to functional parameters as typically observed in atherosclerotic vascular dis-
ease.
1066-193 Endovascular Stent-Graft Placement for Nonsurgical 
Repair of Descending Aortic Perforations: Acute and 
Follow-Up Results
Dierk Scheinert, Andrej Schmidt, Susanne Scheinert, Sven Bräunlich, Hans 
Krankenberg, Giancarlo Biamino, Friedrich Mohr, Heart Center Leipzig, Leipzig, 
Germany
Background: Perforating lesions of the descending thoracic aorta are a life-threatening
condition associated with high morbidity and mortality.
Methods: Between January 1999 and October 2002 a total of 25 consecutive patients (15
male, mean age 63.3 years) underwent percutaneous treatment for perforating lesions in
the descending aorta. In 19 cases (group A) the aortic perforation was due to ruptured
aortic type-B dissections (n=13) or rupture of preexisting atherosclerotic thoracic aneu-
rysms (n=6); 6 patients (group B) were treated for posttraumatic perforations of the
descending aorta. In total 31 endoprostheses were implanted (4 patients with two and 1
patient with three endoprostheses).
Results: The implantation of the endoprosthesis was successfully performed in all cases
without periinterventional complications. In one case implantation of a second endopros-
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